Elutia (ELUT) 17th Annual LD Micro Main Event Conference summary

Product innovation and market opportunity

• EluPro, a newly FDA-approved drug-eluting biologic envelope for pacemakers, is set for full launch in January, targeting a $600 million market with superior clinical benefits and easier use compared to the incumbent TYRX product.

• EluPro addresses key complications in pacemaker implantation, such as migration, fibrosis, and infection, by combining a biological matrix with antibiotics, leading to better patient outcomes and easier procedures for physicians.

• Market research shows 88% of electrophysiologists using TYRX would switch to EluPro, and favorable dynamics exist as EluPro is welcomed by Medtronic's competitors, who control 60% of the market.

• The company is converting 400 existing hospital customers from its previous product, CanGaroo, to EluPro, with a commercial team of 13 direct and 22 contract reps, and strong distributor relationships.

• Revenue growth is currently limited by hospital Value Analysis Committee approvals, which typically take six months, with a full-scale launch and clinical registry planned for Q1 2025.

Competitive landscape and financials

• Medtronic's TYRX is the only other antibiotic-eluting envelope, but is synthetic and limited to changeout procedures, while EluPro can be used in both de novo and changeout cases.

• EluPro is priced at an ASP of about $1,000 and is covered under a global DRG, making reimbursement straightforward for hospitals.

• The company is well-funded, having recently raised $28 million to support the product launch and ongoing operations.

• SimpliDerm, the company’s biologic for breast reconstruction, is growing at a 34% rate with a $13–14 million run rate, and plans are underway to add drug-eluting technology to this product as well.

• The company is fully integrated, with in-house manufacturing, R&D, and sales infrastructure, and is positioned for significant growth.

Strategic vision and future plans

• The company’s strategy leverages its biologics expertise to disrupt synthetic device markets, aiming to capture substantial market share in both cardiac and breast reconstruction segments.

• Full commercial launch of EluPro is set for Q1 2025, with ongoing efforts to secure hospital approvals and build clinical evidence through a registry.

• Expansion of drug-eluting technology to SimpliDerm is expected to further enhance the product’s value proposition and market reach.

• The company’s commercial and distribution partnerships with major device makers like Abbott and Boston Scientific are expected to accelerate adoption.

• Continued focus on innovation and clinical outcomes is central to the company’s growth strategy.